Copyrighted Material
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Treatment Repurposing for Inflammatory Bowel Disease Using Literature-Related Discovery and Innovation Kostoff RN, Briggs MB, Shores DR
ISSN 1007-9327 (print) ISSN 2219-2840 (online) World Journal of Gastroenterology World J Gastroenterol 2020 September 7; 26(33): 4889-5059 Published by Baishideng Publishing Group Inc World Journal of W J G Gastroenterology Contents Weekly Volume 26 Number 33 September 7, 2020 FRONTIER 4889 Treatment repurposing for inflammatory bowel disease using literature-related discovery and innovation Kostoff RN, Briggs MB, Shores DR REVIEW 4900 Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells Polidoro MA, Mikulak J, Cazzetta V, Lleo A, Mavilio D, Torzilli G, Donadon M MINIREVIEWS 4919 Exploring the food-gut axis in immunotherapy response of cancer patients Russo E, Nannini G, Dinu M, Pagliai G, Sofi F, Amedei A ORIGINAL ARTICLE Basic Study 4933 Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice Bluemel S, Wang Y, Lee S, Schnabl B 4945 Resveratrol alleviates intestinal mucosal barrier dysfunction in dextran sulfate sodium-induced colitis mice by enhancing autophagy Pan HH, Zhou XX, Ma YY, Pan WS, Zhao F, Yu MS, Liu JQ Retrospective Study 4960 Effects of denosumab treatment in chronic liver disease patients with osteoporosis Saeki C, Saito M, Oikawa T, Nakano M, Torisu Y, Saruta M, Tsubota A 4972 Bowel function and quality of life after minimally invasive colectomy with D3 lymphadenectomy for right- sided colon adenocarcinoma Lee KM, Baek SJ, Kwak JM, Kim J, Kim SH 4983 Acute liver failure and death -
(12) Patent Application Publication (10) Pub. No.: US 2006/0165636A1 Hasebe Et Al
US 2006O165636A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0165636A1 HaSebe et al. (43) Pub. Date: Jul. 27, 2006 (54) HAIR TREATMENT COMPOSITION AND (52) U.S. Cl. .......................................................... 424/70.14 HAIR COSMETC FOR DAMAGED HAIR (76) Inventors: Kouhei Hasebe, Gifu (JP); Kikumi (57) ABSTRACT Yamada, Gifu (JP) Correspondence Address: The present invention intends to provide a composition for FRISHAUF, HOLTZ, GOODMAN & CHICK, PC hair treatment containing Y-polyglutamic acid or a salt 220 Fifth Avenue thereof, a hair cosmetic for damaged hair containing Such a 16TH Floor composition, and their uses. The composition for hair treat NEW YORK, NY 10001-7708 (US) ment containing Y-polyglutamic acid or a salt thereof and the hair cosmetic for damaged hair of the present invention have (21) Appl. No.: 10/547,492 excellent improvement effects on the strength and frictional (22) PCT Filed: Mar. 3, 2004 force of hair, so that they can provide tension, elasticity, or the like to damage hair to prevent or alleviate split hair and (86). PCT No.: PCT/PO4/O2606 broken hair as well as improvements in combing and touch. (30) Foreign Application Priority Data Furthermore, they also exert effects of moisture retention inherent to Y-polyglutamic acid or a salt thereof, preventing Mar. 10, 2003 (JP)......................................... 2003-62688 or improving effects on the generation of dandruff on the basis of such effects, preventing effects on the feeling of Publication Classification Stickiness or creak, and various effectiveness including (51) Int. Cl. appropriate residual tendency to hair in a simultaneous A6 IK 8/64 (2006.01) manner, respectively. -
Incorporation of Elastase Inhibitor in Silk Fibroin Nanoparticles for Transdermal Delivery
Universidade do Minho Escola de Engenharia Ana Vanessa Fernandes Ferreira Incorporation of Elastase Inhibitor in Silk Fibroin Nanoparticles for Transdermal Delivery Incorporation of Elastase Inhibitor in Silk Fibroin DeliveryNanoparticles for Transdermal Ana Vanessa Fernandes Ferreira Fernandes Ana Vanessa Uminho | 2013 Uminho Outubro de 2013 Universidade do Minho Escola de Engenharia Ana Vanessa Fernandes Ferreira Incorporation of Elastase Inhibitor in Silk Fibroin Nanoparticles for Transdermal Delivery Dissertação de Mestrado Mestrado em Bioengenharia Trabalho efetuado sob a orientação do Professor Doutor Artur Cavaco Paulo e coorientação de Doutora Ana Sofia Lemos Machado Abreu Outubro de 2013 DECLARAÇÃO Nome: Ana Vanessa Fernandes Ferreira Endereço eletrónico: [email protected] Título da dissertação: Incorporação de Inibidor de Elastase em Nanopartículas de Fibroína de Seda para Aplicações Transdérmicas (Incorporation of Elastase Inhibitor in Silk Fibroin Nanoparticles for Transdermal Delivery) Orientador (es): Professor Artur Cavaco Paulo e Ana Sofia Lemos Machado Abreu Ano de conclusão: 2013 Designação do Mestrado: Mestrado em Bioengenharia É AUTORIZADA A REPRODUÇÃO INTEGRAL DESTA TESE/TRABALHO APENAS PARA EFEITOS DE INVESTIGAÇÃO, MEDIANTE DECLARAÇÃO ESCRITA DO INTERESSADO, QUE A TAL SE COMPROMETE. Universidade do Minho, 29/11/2013 Assinatura: ____________________________________________________________________________ No amount of experimentation can ever prove me right; a single experiment can prove me wrong. - Albert Einstein To my beloved family Este trabalho não teria sido possível sem a colaboração das pessoas que me ajudaram a concretizá-lo,Agradecimentos tanto a nível profissional / Acknoledgments como pessoal. Agradeço ao meu orientador, Professor Dr. Artur Cavaco Paulo, pela oportunidade de ingressar no seu grupo de trabalho e neste projeto de investigação, por ter confiado e acreditado nas minhas capacidades e potencial, pelo seu apoio e incentivo nestes últimos dois anos. -
Biomolecules of Interest Present in the Main Industrial Wood Species Used in Indonesia-A Review
Tech Science Press DOI: 10.32604/jrm.2021.014286 REVIEW Biomolecules of Interest Present in the Main Industrial Wood Species Used in Indonesia-A Review Resa Martha1,2, Mahdi Mubarok1,2, Wayan Darmawan2, Wasrin Syafii2, Stéphane Dumarcay1, Christine Gérardin Charbonnier1 and Philippe Gérardin1,* 1Université de Lorraine, Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement, Laboratoire d'Etudes et de Recherche sur le Matériau Bois, Nancy, France 2Department of Forest Products, Faculty of Forestry and Environment, Institut Pertanian Bogor, Bogor University, Bogor, Indonesia *Corresponding Author: Philippe Gérardin. Email: [email protected] Received: 17 September 2020 Accepted: 20 October 2020 ABSTRACT As a tropical archipelagic country, Indonesia’s forests possess high biodiversity, including its wide variety of wood species. Valorisation of biomolecules released from woody plant extracts has been gaining attractive interests since in the middle of 20th century. This paper focuses on a literature review of the potential valorisation of biomole- cules released from twenty wood species exploited in Indonesia. It has revealed that depending on the natural origin of the wood species studied and harmonized with the ethnobotanical and ethnomedicinal knowledge, the extractives derived from the woody plants have given valuable heritages in the fields of medicines and phar- macology. The families of the bioactive compounds found in the extracts mainly consisted of flavonoids, stilbenes, stilbenoids, lignans, tannins, simple phenols, terpenes, terpenoids, alkaloids, quinones, and saponins. In addition, biological or pharmacological activities of the extracts/isolated phytochemicals were recorded to have antioxidant, antimicrobial, antifungal, anti-inflammatory, anti-diabetes, anti-dysentery, anticancer, analgesic, anti-malaria, and anti-Alzheimer activities. -
Mónia Andreia Rodrigues Martins Estudos Para O
Universidade de Aveiro Departamento de Química 2017 MÓNIA ANDREIA ESTUDOS PARA O DESENVOLVIMENTO DE NOVOS RODRIGUES MARTINS PROCESSOS DE SEPARAÇÃO COM TERPENOS E SUA DISTRIBUIÇÃO AMBIENTAL STUDIES FOR THE DEVELOPMENT OF NEW SEPARATION PROCESSES WITH TERPENES AND THEIR ENVIRONMENTAL DISTRIBUTION Universidade de Aveiro Departamento de Química 2017 MÓNIA ANDREIA ESTUDOS PARA O DESENVOLVIMENTO DE NOVOS RODRIGUES MARTINS PROCESSOS DE SEPARAÇÃO COM TERPENOS E SUA DISTRIBUIÇÃO AMBIENTAL STUDIES FOR THE DEVELOPMENT OF NEW SEPARATION PROCESSES WITH TERPENES AND THEIR ENVIRONMENTAL DISTRIBUTION Tese apresentada à Universidade de Aveiro para cumprimento dos requisitos necessários à obtenção do grau de Doutor em Engenharia Química, realizada sob a orientação científica do Professor Doutor João Manuel da Costa e Araújo Pereira Coutinho, Professor Catedrático do Departamento de Química da Universidade de Aveiro, e do Professor Doutor Simão Pedro de Almeida Pinho, Professor Coordenador da Escola Superior de Tecnologia e Gestão do Instituto Politécnico de Bragança. Apoio financeiro da FCT e do FSE no âmbito do III Quadro Comunitário de Apoio (SFRH/BD/87084/2012). Aos meus pais. o júri presidente Prof. Doutor Joaquim Manuel Vieira professor catedrático no Departamento de Engenharia Cerâmica e do Vidro da Universidade de Aveiro Prof. Doutora Isabel Maria Almeida Fonseca professora associada com agregação da Faculdade de Ciências e Tecnologia da Universidade de Coimbra Prof. Doutor Héctor Rodríguez Martínez professor associado do Departamento de Engenharia Química da Universidade de Santiago de Compostela Prof. Doutor Luís Manuel das Neves Belchior Faia dos Santos professor associado da Faculdade de Ciências da Universidade do Porto Prof. Doutor Simão Pedro de Almeida Pinho professor coordenador na Escola Superior de Tecnologia e Gestão do Instituto Politécnico de Bragança Prof. -
Dihydromyricetin
Last updated on May 29, 2020 Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. Dihydromyricetin Evidence Summary DHM has anti-inflammatory, antioxidant, pro-autophagic, and energy metabolism regulating properties due to activation of sirtuins, AMPK, and Nrf2, but poor bioavailability hinders clinical utility. Neuroprotective Benefit: DHM shows anti-inflammatory, antioxidant, and pro-autophagy properties which reduce cognitive impairment in animal models, but a similar level of benefit to humans is unlikely due to low bioavailability. Aging and related health concerns: DHM shows anti-inflammatory and antioxidant properties, and may favorably regulate metabolism by boosting irisin levels, improving insulin sensitivity, and enhancing lipid metabolism in animals; benefits less clear in humans. Safety: DHM has a good safety record in short term RCTs and animal studies, which may be due to low bioavailability. Pharmacokinetic properties may differ across patient populations, and may have drug interactions due to projected CYP inhibition activity. 1 Last updated on May 29, 2020 Availability: OTC Dose: Therapeutic dose not Chemical formula: C15H12O8 established MW: 320.25 g/mol Half-life: 2 hours (in rats) BBB: Penetrant Clinical trials: Type 2 diabetes Observational studies: None (n=77, NAFLD (n=60) Source: PubChem What is it? Dihydromyricetin (DHM), also called ampelopsin, is the major flavonoid in Ampelopsis plants, primarily in the species grossedentata [1]. -
Cosmetic Composition Containing Polyorganosiloxane-Containing Epsilon-Polylysine Polymer, and Polyhydric Alcohol, and Production Thereof
Europäisches Patentamt *EP001604647A1* (19) European Patent Office Office européen des brevets (11) EP 1 604 647 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: A61K 7/48, A61K 7/06, 14.12.2005 Bulletin 2005/50 A61K 7/02, C08G 81/00, C08G 77/452, C08G 77/455, (21) Application number: 05010234.2 C08L 83/10 (22) Date of filing: 11.05.2005 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • Kawasaki, Yuji HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR Ibi-gun Gifu 501-0521 (JP) Designated Extension States: • Hori, Michimasa AL BA HR LV MK YU Gifu-shi Gifu 500-8286 (JP) • Yamamoto, Yuichi (30) Priority: 12.05.2004 JP 2004141778 5-1 Goikaigan Ichiharashi Chiba 290-8551 (JP) • Hiraki, Jun (71) Applicants: Tokyo 104-8555 (JP) • Ichimaru Pharcos Co., Ltd. Motosu-shi, Gifu 501-0475 (JP) (74) Representative: HOFFMANN EITLE • Chisso Corporation Patent- und Rechtsanwälte Osaka-shi, Osaka-fu 530-0005 (JP) Arabellastrasse 4 81925 München (DE) (54) Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof (57) It has been desired to develop a highly preserv- by reducing the amount of antibacterial preservative ative and antibacterial cosmetic composition that can agent to be used. easily be applied to both emulsion and non-emulsion There is provided a cosmetic composition compris- type cosmetics. It has also been desired to develop a ing one or a combination of two or more of polyorganosi- method of improving a preservative and/or antibacterial loxane-containing epsilon-polylysine compounds ob- effect(s) of a cosmetic composition comprising polyor- tained by reacting epsilon-polylysine with polyorganosi- ganosiloxane-containing epsilon-polylysine and there- loxane or a physiologically acceptable salt thereof, and polyhydric alcohol. -
Transnasal Delivery of Fluoxetine HCL to Brain for Treating Depression
Theranostics of Brain, Spine & Neural Disorders ISSN: 2641-8096 Research Article Theranostics Brain,Spine & Neural Disord Volume 4 Issue 2 - November 2019 Copyright © All rights are reserved by Avinash Ramrao Tekade DOI: 10.19080/JOJS.2019.04.555633 Transnasal Delivery of Fluoxetine HCL to Brain for Treating Depression Sagar Atmaram Aher and Avinash Ramrao Tekade* Department of Pharmaceutics and Pharmaceutical QA, Marathwada MitraMandal’s College of Pharmacy, India Submission: September 17, 2019; Published: November 15, 2019 *Corresponding author: Avinash R Tekade, Department of Pharmaceutics and Pharmaceutical QA, Marathwada Mitra Mandal’s College of Pharmacy, Thergaon, Pune, Maharashtra 411033, India Abstract The objective of this study is to formulate a mucoadhesive microemulsion containing Fluoxetine HCl as antidepressant and Cedar oil as penetration enhancer. Water titration method was used to formulate the microemulsion using two different ratios of selected surfactant and cosurfactant (Tween 80 and Propylene Glycol). The prepared microemulsion showed mean globule size of 303.84nm. The prepared microemulsion ex vivo diffusion is non-irritant for nasal mucosa which was confirmed by ciliotoxicity study using sheep nasal mucosa. It is clearly evident from study that mucoadhesive microemulsion can deliver drug for longer time, the initial release was burst release in the first hour followed by thesustained brain by for nasal next administration.three hours, and increased diffusion will definitely help in reducing dose related side effects -
(12) Patent Application Publication (10) Pub. No.: US 2013/0209617 A1 Lobisser Et Al
US 20130209.617A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0209617 A1 Lobisser et al. (43) Pub. Date: Aug. 15, 2013 (54) COMPOSITIONS AND METHODS FOR USE Publication Classification IN PROMOTING PRODUCE HEALTH (51) Int. Cl. (75) Inventors: George Lobisser, Bainbridge Island, A23B 7/16 (2006.01) WA (US); Jason Alexander, Yakima, (52) U.S. Cl. WA (US); Matt Weaver, Selah, WA CPC ........................................ A23B 7/16 (2013.01) (US) USPC ........... 426/102: 426/654; 426/573; 426/601; 426/321 (73) Assignee: PACE INTERNATIONAL, LLC, Seattle, WA (US) (57) ABSTRACT (21) Appl. No.: 13/571,513 Provided herein are compositions comprising one or more of (22) Filed: Aug. 10, 2012 a stilbenoid, stilbenoid derivative, stilbene, or stilbene deriva tive and a produce coating. The resulting compositions are Related U.S. Application Data coatings which promote the health of fruit, vegetables, and/or (60) Provisional application No. 61/522,061, filed on Aug. other plant parts, and/or mitigate decay of post-harvest fruit, 10, 2011. Vegetables, and/or other plant parts. Patent Application Publication Aug. 15, 2013 Sheet 1 of 10 US 2013/0209.617 A1 | s N i has() 3 S s c e (9) SSouffley Patent Application Publication Aug. 15, 2013 Sheet 2 of 10 US 2013/0209.617 A1 so in a N s H N S N N. sr N re C c g o c (saulu) dae. Patent Application Publication Aug. 15, 2013 Sheet 3 of 10 US 2013/0209.617 A1 N Y & | N Y m N 8 Š 8 S. -
Pharmacological Potential of Ampelopsin in Rattan Tea
Available online at www.sciencedirect.com Food Science and Human Wellness 1 (2012) 14–18 Pharmacological potential of ampelopsin in Rattan tea a a,b,∗ Xianjuan Kou , Ning Chen a College of Health Science, Wuhan Sports University, Wuhan 430079, China b The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA Received 23 July 2012; received in revised form 28 July 2012; accepted 29 August 2012 Abstract Rattan tea, made from the leaves of Ampelopsis grossedentata, may potentially perform multiple pharmacological roles, including anti-bacterial, anti-cancer, antioxidant, hepatoprotective and anti-hypertension functions. These beneficial functions of Rattan tea are strongly associated with the bioactivity of ampelopsin, a major flavonoid compound in Rattan tea. In this review, we summarize current research related to the bioactivity and pharmacological mechanisms of ampelopsin, which will provide a better reference for its potential application in the prevention of chronic diseases. © 2012 Production and hosting by Elsevier B.V. on behalf of Beijing Academy of Food Sciences. Keywords: Ampelopsin; Rattan tea; Flavonoid; Pharmacological potential; Chronic disease 1. Introduction functions and corresponding action mechanisms, as well as potential human health benefits of ampelopsin. Rattan tea is a traditional Chinese herbal remedy prepared from the stems and leaves of the plant Ampelopsis grossedentata. 2. Anti-bacterial and anti-inflammatory effects Ampelopsin is one of the most important flavonoids found in Rattan tea. As a dihydromyricetin (DMY), ampelopsin was first Ampelopsin in crude plant extracts has been applied to alle- isolated from Ampelopsis meliaefolia by Kotake and Kubota in viate inflammatory diseases as a broad-spectrum anti-bacterial 1940, and was later reported as a major bioactive component in drug for several centuries. -
Terpenoids [Compatibility Mode].Pdf
Terpenoids Dr. Amol Kharat Objectives • To study the Terpenoids in the form of Meaning, Different types Properties, occurrences, uses Isolation Method General Biogenetic Pathway Pharmacognostic account of different drug con taining important constituents Terpenoids. INTRODUCTION Terpenoids are the secondary metabolites synthesized by plants, marine organisms and fungi by head to tail joining of isoprene units . They are also found to occur in rocks, fossils and animal kingdom. Isoprene The terpenoids , sometimes referred to as isoprenoids , are a large and diverse class of naturally-occurring organic chemicals similar to terpenes, derived from five-carbon isoprene units assembled and modified in thousands of ways. Most are multicyclic structures that differ from one another not only in functional groups but also in their basic carbon skeletons . These lipids can be found in all classes of living things, and are the largest group of natural products. CALASSFICATION TYPE OF NUMBER OF ISOPRENE TERPENOIDS CARBON ATOMS UNITS hemiterpene C5 one monoterpenoid C10 two sesquiterpenoid C15 three diterpenoid C20 four sesterterpenoid C25 five triterpenoid C30 six tetraterpenoid C40 eight NOTE hemi = half di = two : sesqui = one and a half tri = three tetra = four Mnonoterpenoids Monoterpenes are a class of terpenes that consist of two isoprene units and have the molecular formula C 10 H16 . Monoterpenes may be linear (acyclic) or contain rings. Biochemical modifications such as oxidation or rearrange- ment produce the related monoterpenoids. Mnonoterpenoids Acyclic monoterpenoid: Bicyclic monoterpenoid CHO CH 2 OH n e ro l g era n ia l ¦Â-m y r c e n e ¦Á ---ppp i nene Monocyclic monoterpenodi OH O OH O d-borneol l-menthol menthone cin eole Acyclic monoterpenoid Acyclic monoterpenoid Biosynthetically, isopentenyl pyrophosphate( 异戊烯 焦磷酸) and dimethylallyl pyrophosphate ( 二甲基丙烯焦 磷酸酯) are combined to form geranyl pyrophosphate (牻牛儿醇焦磷酸酯). -
Oral Administration of Ampelopsin Protects Against Acute Brain Injury in Rats Following Focal Cerebral Ischemia
EXPERIMENTAL AND THERAPEUTIC MEDICINE 13: 1725-1734, 2017 Oral administration of ampelopsin protects against acute brain injury in rats following focal cerebral ischemia XIAO-LI YE1, LING-QUN LU2, WEI LI2, QI LOU2, HONG-GANG GUO2 and QIAO-JUAN SHI2 1Department of Pharmacy, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003; 2Experimental Animal Center, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang 310013, P.R. China Received August 11, 2015; Accepted December 19, 2016 DOI: 10.3892/etm.2017.4197 Abstract. Ampelopsin (AMP) is isolated from the Chinese of the current study indicate a therapeutic role for AMP in the medicinal herb Ampelopsis grossedentata (Hand-Mazz) and treatment of ischemic stroke. has been associated with numerous biological and pharmaco- logical activities. However, it is not clear whether AMP has Introduction a direct protective effect on cerebral ischemia reperfusion injury. Therefore, the present study investigated its role in Stroke is a major life-threatening disease with a worldwide acute brain injury following focal cerebral ischemia in rats. incidence of approximately two in 1,000 per year, and a The current study induced transient focal cerebral ischemia annual 8% mortality rate (1). Despite the development of by performing middle cerebral artery occlusion (MCAO) shock therapy and the application of advanced thrombolytic for 60 min, followed by 24 h of reperfusion. Rats were agents and intravascular procedures, clinical therapy of the exposed to 40, 80 and 160 mg/kg AMP by oral administra- debilitating disorder remains unsatisfactory (2,3). Therefore, tion 30 min prior to MCAO and the cysteinyl leukotriene neuroprophylaxis against stroke has received more attention.